Respiratory News and Research RSS Feed - Respiratory News and Research

Mayo Clinic expert explains difference between severe sepsis and septic shock

Mayo Clinic expert explains difference between severe sepsis and septic shock

Sepsis can be a dangerous complication of almost any type of infection, including influenza, pneumonia and food poisoning; urinary tract infections; bloodstream infections from wounds; and abdominal infections. [More]
Atmospheric oxygen may play role in lung carcinogenesis, new study suggests

Atmospheric oxygen may play role in lung carcinogenesis, new study suggests

The ancient physician/alchemist, Paracelsus, said: "The dose makes the poison." According to a new study published in PeerJ, even oxygen may fall prey to the above adage. While essential to human life, aspects of oxygen metabolism may promote cancer. Capitalizing on the inverse relationship of oxygen concentration with elevation, researchers found lower rates of lung cancer at higher elevations, a trend that did not extend to non-respiratory cancers, suggesting that carcinogen exposure occurs via inhalation. [More]
New way to measure upper extremity movement in muscular dystrophy patients

New way to measure upper extremity movement in muscular dystrophy patients

Researchers at Nationwide Children's Hospital have developed a way to measure upper extremity movement in patients with muscular dystrophy using interactive video game technology. Their hope is to expand inclusion criteria for clinical trials to incorporate patients using wheelchairs. [More]
QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer. [More]
Radon linked to lung cancer risk in nonsmokers

Radon linked to lung cancer risk in nonsmokers

Each year, radon kills more people than home fires, drowning, falls or drunk driving. It is the number one cause of lung cancer in nonsmokers, taking some 21,000 lives annually. [More]
Two new ODYSSEY trials meet primary efficacy endpoints

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints. [More]
Better physical functioning associated with remission of general anxiety, PTSD symptoms

Better physical functioning associated with remission of general anxiety, PTSD symptoms

In a two-year longitudinal study involving 13 intensive care units in four U.S. hospitals, researchers found that better physical functioning — basic and complex activities considered essential for maintaining independence — is associated with remission of general anxiety and post-traumatic stress disorder (PTSD) symptoms. These findings may help clinicians be better prepared for caring for the growing number of survivors of critical illness, potentially leading to a better quality of recovery for patients. [More]
EarlySense brings Bedside Monitor and Central Display System to Canadian Market

EarlySense brings Bedside Monitor and Central Display System to Canadian Market

EarlySense, the market leader in contact-free monitoring solutions today announced an approval to distribute its latest Bedside Monitor and Central Display System in the Canadian Market. EarlySense is bringing to Canada a unique solution that empowers clinicians to provide efficient, safe care based on early indication of high risk situations for falls, pressure ulcers or deterioration such as caused by Opioid therapy. [More]
Taiwan Biophotonic releases DOE reflective sensor for fingerless wrist-worn pulse oximeters

Taiwan Biophotonic releases DOE reflective sensor for fingerless wrist-worn pulse oximeters

Taiwan Biophotonic Co., a leading provider of non-invasive vital signs sensing solutions, today announced the release of its DOE reflective sensor for fingerless wrist-worn pulse oximeters, which makes a quantum leap forward in the wearable healthcare and medical devices. [More]
BrainStorm's phase 2a ALS study meets primary endpoint

BrainStorm's phase 2a ALS study meets primary endpoint

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadassah Medical Center in Jerusalem. [More]
FDA receives Actavis' NDA resubmission for cariprazine

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors. [More]
Outbreaks of infectious diseases offer lessons for critical care providers

Outbreaks of infectious diseases offer lessons for critical care providers

Outbreaks of infectious diseases, such as Ebola in West Africa, offer insight for how healthcare professionals can respond more effectively to current and future challenges, according to editors of the American Journal of Critical Care. [More]
Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars. [More]
Loyola to be included in "Guinness World Records" 2015 edition for neonatal care

Loyola to be included in "Guinness World Records" 2015 edition for neonatal care

Loyola University Medical Center will be included in the "Guinness World Records" 2015 edition for caring for the world's smallest baby. [More]
Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology. [More]
Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA. [More]
Negative health effects of severe obesity

Negative health effects of severe obesity

The negative health effects of severe obesity are very well known and have been thoroughly documented, yet obesity levels in the United States continue to remain stubbornly high. Many of these repercussions are life threatening and include heart attack, stroke, and a greatly increased chance of developing cancer. [More]
Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension. [More]
FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. [More]
Periods of extreme heat associated with increased hospitalization risk for older adults

Periods of extreme heat associated with increased hospitalization risk for older adults

Between 1999 and 2010, periods of extreme heat in the U.S. were associated with an increased risk of hospitalization for older adults for fluid and electrolyte disorders, kidney failure, urinary tract infections, septicemia and heat stroke, according to a study in the December 24/31 issue of JAMA. [More]